FeLV treatment strategies and prognosis

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 27, Issue 2 SUPPL., 2005, Pages 17-26

  Hartmann, Katrin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 14944345670     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Cotter SM: Management of healthy feline leukemia virus-positive cats. JAVMA 199:1470-1473, 1991.
2. Levy J, Richards J, Edwards D, et al: Feline retrovirus testing and management. Compend Contin Educ Pract Vet 22:652-657, 2001.
3. Tavares L, Roneker C, Postie L, de Noronha F: Testing of nucleoside analogues in cats infected with feline leukemia virus: A model. Intervirology 30:26-35, 1989.
4. Greene CE, Watson ADJ: Antiviral drugs, in Greene CE (ed): Infectious Diseases of the Dog and Cat, ed 2. Philadelphia, WB Saunders, 1998, pp 6-9.
5. Hartmann K, Brunner K, Lutz H: Treatment of feline leukemia virus infection with 3-azido-2,3-dideoxythymidine and human alpha-interferon. Proc ACVIM 20:779, 2002.
6. Hartmann K, Donath A, Beer B: Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 35:167-175, 1992.
7. Hartmann K, Donath A, Kraft W: AZT in the treatment of feline immunodeficiency virus infection: Part 1. Feline Pract 5:16-21, 1995.
8. Hartmann K, Donath A, Kraft W: AZT in the treatment of feline immunodeficiency virus infection: Part 2. Feline Pract 6:13-20, 1995.
9. Hoover EA, Zeidner NS, Perigo NA: Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy. Intervirology 30:12-25, 1989.
10. Polas PJ, Swenson CL, Sams R: In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother 34:1414-1421, 1990.
11. Greene CE, Watson ADJ: Antimicrobial drug formulary, in Greene CE (ed): Infectious Diseases of the Dog and Cat, ed 2. Philadelphia, WB Saunders, 1998, pp 790-919.
12. Swenson CL, Polas PJ, Cheney CM, et al: Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro. Am J Vet Res 52:2010-2015, 1991
13. Ryrfeldt A, Nordgren T, Lundstrom J: Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs. Fundam Appl Toxicol 18:126-130, 1992.
14. De Clercq E: Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 8:9-22, 1979.
15. Cogan DC, Cotter SM, Kitchen LW: Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats. Am J Vet Res 47:2230-2232, 1986.
16. Abkowitz JL: Retrovirus-induced feline pure red blood cell aplasia: Pathogenesis and response to suramin. Blood 77:1442-1451, 1991.
17. Cotter SM: Feline viral neoplasia, in Greene CE (ed): Infectious Diseases of the Dog and Cat, ed 2. Philadelphia, WB Saunders, 1998, pp 71-84.
18. Zeidner NS, Rose LM, Mathiason-Dubard CK, et al: Zidovudine in combination with alpha Interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). J Acquir Immune Defic Syndr 3:787-796, 1990.
19. Jameson P, Essex M: Inhibition of feline leukemia virus replication by human leukocyte interferon. Antiviral Res 3:115-120, 1983.
20. Zeidner NS, Myles MH, Mathiason-DuBard CK, et al: Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 34:1749-1756, 1990.
21. Cummins JM, Tompkins MB, Olsen RG, et al: Oral use of human alpha interferon in cats. J Biol Response Mod 7:513-523, 1988.
22. Tomkins MB, Cummins JM: Response of FeLV-induced nonregenerative anemia to oral administration of a bovine interferon-containing preparation. Feline Pract 12:6-15, 1982.
23. Steed VP: Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Pract 17:24-30, 1987.
24. Weiss RC, Cummins JM, Richards AB: Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. JAVMA 199:1477-1481, 1991.
25. McCaw DL, Boon GD, Jergens AE, et al: Immuno-modulation therapy for feline leukemia virus infection. J Am Anim Hosp Assoc 37:356-363, 2001.
26. Rogers R, Merigan TC, Hardy WD Jr, et al: Cat Interferon inhibits feline leukaemia virus infection in cell culture. Nat New Biol 237:270-271, 1972.
27. Maynard L, De Mari K, Lebreux B: Efficacy of a recombinant feline omega interferon in the treatment of symptomatic FeLV- or FeLV- and FIV-positive cats. Proc ESVM 10:122a, 2000.
28. Hörber D, Mayr B: Paramunization of FeLV-positive cats with PIND-AVI. Tierärztl Prax 19:311-314, 1991.
29. Hartmann K, Block A, Ferk G, et al: Treatment of feline leukemia virus-infected cats with paramunity inducer. Vet Immunol Immunopathol 65:267-275, 1998.
30. Hartmann K, Block A, Ferk G, et al: Treatment of feline leukemia virus (FeLV) infection. Vet Microbiol 69:111-113, 1999.
31. Sheets MA, Unger BA, Giggleman GF Jr, Tizard IR: Studies of the effect of acemannan on retrovirus infections: Clinical stabilization of feline leukemia virus-infected cats. Mol Biother 3:41-45, 1991.
32. Day NK, Engelman RW Liu WT, et al: Remission of lymphoma leukemia in cats following ex vivo immunosorption therapy using Staphylococcus protein A. J Biol Response Mod 3:278-285, 1984.
33. Jones FR, Grant CK, Snyder HW Jr: Lymphosarcoma and persistent feline leukemia virus infection of pet cats: A system to study responses during extracorporeal treatments. J Biol Response Mod 3:286-292, 1984.
34. Liu WT, Engelman RW, Trang LQ, et al: Appearance of cytotoxic antibody to viral gp70 on feline lymphoma cells (FL-74) in cats during ex vivo immunoadsorption therapy: Quantitation, characterization, and association with remission of disease and disappearance of viremia. Proc Natl Acad Sci USA 81:3516-3520, 1984.
35. Liu WT, Good RA, Trang LQ, et al: Remission of leukemia and loss of feline leukemia virus in cats injected with Staphylococcus protein A: Association with increased circulating interferon and complement-dependent cytotoxic antibody. Proc Natl Acad Sci U S A 81:6471-6475, 1984.
36. Engelman RW, Tyler RD, Trang LQ, et al: Clinicopathologic responses in cats with feline leukemia virus-associated leukemia-lymphoma treated with staphylococcal protein A. Am J Pathol 118:367-378, 1985.
37. Snyder HW Jr, Ernst NR, Grosmaire LS, et al: Selective removal of antigen-complexed IgG from cat plasma by adsorption onto a protein A-silica matrix. J Immunol Methods 101:209-217, 1987.
38. Weiss RC: Immunotherapy for feline leukemia, using staphylococcal protein A or heterologous interferons: Im munopharmacologic actions and potential use. JAVMA 192:681-684, 1988.
39. Harper HD, Sjoquist J, Hardy WD Jr, Jones FR: Antitumor activity of protein A administered intravenously to pet cats with leukemia or lymphosarcoma. Cancer 55:1863-1867, 1985.
40. Megid J, Kaneno R: Natural killer activity in mice infected with rabies virus and submitted to P. acnes (Propionibacterium acnes) as immunomodulator. Comp Immunol Microbiol Infect Dis 23:91-97, 2000.
41. Levy JK: FeLV and non-neoplastic FeLV-related disease, in Ettinger SJ, Feldman EC (eds): Textbook of Veterinary Internal Medicine. Philadelphia, WB Saunders, 2000, pp 424-432.
42. Lies M: Volume of opinion warrants merit. Vet Forum 6:42, 1990.
43. Greene CE: Immunoprophylaxis and immunotherapy, in Greene CE (ed): Infectious Diseases of the Dog and Cat, ed 2. Philadelphia, WB Saunders, 1998, pp 717-750.
44. Bachman D, Cockerell GL, de Noronha F, Rapp HJ: Effect of Bacille Calmette-Guerin immunotherapy on feline sarcoma virus-induced neoplasms in the cat. Am J Vet Res 43:475-80, 1982.
45. Armstrong PJ: Systemic Serratia marcescens infections in a dog and a cat. JAVMA 184:1154-1158, 1984.
46. Elmslie RE, Ogilvie GK, Dow SW, et al: Evaluation of a biologic response modifier derived from Serratia marcescens: Effects on feline macrophages and usefulness for the prevention and treatment of viremia in feline leukemia virus-infected cats. Mol Biother 3:231-238, 1991.
47. Dillon R: Feline dirofilariasis. Vet Clin North Am Small Anim Pract 14:1185-1199, 1984.
48. Reinemeyer CR, Faulkner CT, Assadi-Rad AM, et al: Comparison of the efficacies of three heartworm preventives against experimentally induced infections with Ancylostoma caninum and Toxocara canis in pups. JAVMA 206:1710-1715, 1995.
49. Kitchen LW, Mather FJ, Cotter SM: Effect of continuous oral diethylcarbamazine treatment on lymphocyte counts of feline leukemia virus-infected cats. J Clin Lab Immunol 27:179-181, 1988.
50. Kitchen LW, Mather FJ: Hematologic effects of short-term oral diethylcarbamazine treatment given to chronically feline leukemia virus-infected cats. Cancer Lett 45:183-187, 1989.
51. Nelson P, Sellon R, Novotney C, et al: Therapeutic effects of diethylcarbamazine and 3'-azido-3'-deoxythymidine on feline leukemia virus lymphoma formation. Vet Immunol Immunopathol 46:181-194, 195.
52. Bunch SE: Hepatotoxicity associated with pharmacologic agents in dogs and cats. Vet Clin North Am Small Anim Pract 23:659-670, 1993.